Pfizer在2026年1月批准出售糖尿病和肥胖药物Ecnoglutide。 Pfizer gains rights to sell ecnoglutide in China, a diabetes and obesity drug approved in January 2026.

Pfizer已获得专有权利将中国大陆上由中国杭州西风生物科学公司研发的糖尿病和肥胖药物Ecnoglutide商业化。 Pfizer has acquired exclusive rights to commercialize ecnoglutide, a diabetes and obesity drug developed by China’s Hangzhou Sciwind Biosciences, in mainland China. 这笔可能价值4.95亿美元的里程碑付款的交易,是在2026年1月中国NMPA批准2型糖尿病后进行的。 The deal, potentially worth $495 million in milestone payments, follows the drug’s January 2026 approval by China’s NMPA for type 2 diabetes. 埃克诺格卢提德正在进行肥胖治疗的审查,并在临床试验中显示出显著的减肥效果. Ecnoglutide is under review for obesity treatment and has shown significant weight loss results in clinical trials. Pfizer将处理商业化问题,而Sciwind则保留监管和制造责任。 Pfizer will handle commercialization while Sciwind retains regulatory and manufacturing responsibilities. 该协定反映出国际制药公司与中国生物技术合作,获得创新的GLP-1疗法的趋势日益增长。 The agreement reflects a growing trend of international pharmaceutical companies partnering with Chinese biotechs to access innovative GLP-1 therapies.